CDK8 and ovarian cancer: 30,32 Notably, CDK8/19 inhibitors have reached clinical trials for solid tumors and leukemias (clinicaltrials.govNCT03065010, NCT04021368, NCT05052255, NCT05300438), however no prior study has assessed their utility in ovarian cancer models.